AGM
LSTA icon

Alpine Global Management’s Lisata Therapeutics LSTA Stock Holding History

Alpine Global Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-74
Closed -$21K – 498
2015
Q2 		$21K Buy
+74
New +$27.5K ﹤0.01% 925
2015
Q1 		– Sell
-99
Closed -$56K – 417
2014
Q4 		$56K Buy
+99
New +$67.4K 0.01% 535

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Alpine Global Management's LSTA Position: Q3 2015 in Review

Alpine Global Management sold out of Lisata Therapeutics (LSTA) in Q3 2015, closing a stake of 74 shares — an estimated $21K sold.

Alpine Global Management first reported a position in LSTA in Q4 2014 and held it in 2 quarters. The position peaked at $56K in Q4 2014. 43 funds tracked by Wall St. Rank hold LSTA as of Q3 2015.

  • Alpine Global Management reported no remaining Lisata Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Alpine Global Management sold 74 Lisata Therapeutics shares in Q3 2015, an estimated $21K.
  • Alpine Global Management first reported a position in Lisata Therapeutics in Q4 2014 and held it in 2 quarters.
  • Alpine Global Management's Lisata Therapeutics position peaked at $56K in Q4 2014.
  • 43 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2015.

Based on Alpine Global Management's 13F filing for Q3 2015, filed 10 Nov 2015.